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 Background The clinical impact of the biological heterogeneity within HER2-positive (HER2+) breast cancer is not fully under-
stood. Here, we evaluated the molecular features and survival outcomes of the intrinsic subtypes within HER2+ 
breast cancer.
 Methods We interrogated The Cancer Genome Atlas (n  =  495) and Molecular Taxonomy of Breast Cancer International 
Consortium (METABRIC) datasets (n = 1730) of primary breast cancers for molecular data derived from DNA, RNA 
and protein, and determined intrinsic subtype. Clinical HER2 status was defined according to American Society 
of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines or DNA copy-number aberration 
by single nucleotide polymorphism arrays. Cox models tested the prognostic significance of each variable in 
patients not treated with trastuzumab (n = 1711).
 Results Compared with clinically HER2 (cHER2)-negative breast cancer, cHER2+ breast cancer had a higher frequency 
of the HER2-enriched (HER2E) subtype (47.0% vs 7.1%) and a lower frequency of Luminal A  (10.7% vs 39.0%) 
and Basal-like (14.1% vs 23.4%) subtypes. The likelihood of cHER2-positivity in HER2E, Luminal B, Basal-like and 
Luminal A subtypes was 64.6%, 20.0%, 14.4% and 7.3%, respectively. Within each subtype, only 0.3% to 3.9% of 
genes were found differentially expressed between cHER2+ and cHER2-negative tumors. Within cHER2+ tumors, 
HER2 gene and protein expression was statistically significantly higher in the HER2E and Basal-like subtypes than 
either luminal subtype. Neither cHER2 status nor the new 10-subtype copy number-based classification system 
(IntClust) added independent prognostic value to intrinsic subtype.
 Conclusions When the intrinsic subtypes are taken into account, cHER2-positivity does not translate into large changes in 
the expression of downstream signaling pathways, nor does it affect patient survival in the absence of HER2 
targeting.
  JNCI J Natl Cancer Inst (2014) 106(8): dju152 doi:10.1093/jnci/dju152
HER2/ERBB2 is an oncogene coding for a tyrosine kinase recep-
tor that activates critical signal transduction pathways resulting 
in an aggressive phenotype and poor outcome in breast cancer 
(1–3). Fortunately, amplification and/or overexpression of HER2 
in breast cancer (HER2+) are associated with a high benefit from 
anti-HER2 therapies in combination with chemotherapy (4–8). In 
addition, dual HER2 targeting without chemotherapy is showing 
promising activity in a subset of HER2+ tumors (9,10).
To date, HER2+ breast cancer has been envisioned as a single 
disease entity, as hormone receptor-positive breast cancer had also 
been initially considered a uniform disease subtype. While the rea-
son to consider HER2+ breast cancer as a single disease subtype 
may have been dictated by the dominant role of the HER2 recep-
tor itself as well as the availability of the anti-HER2 agent trastu-
zumab, it is now increasingly apparent that HER2+ is clinically and 
biologically heterogeneous (11–17).
Gene expression profiling has identified four main intrinsic 
molecular subtypes of breast cancer (Luminal A, Luminal B, HER2 
enriched [HER2E], and Basal-like) with different outcomes and 
responses to therapy (18–30). Among the different subtypes, the 
HER2E subtype is characterized by the high expression of HER2-
regulated genes and low expression of luminal-related (12–15).
Although the HER2E subtype largely overlaps with cHER2-
positivity as determined by immunohistochemistry (IHC) and/
or fluorescence in situ hybridization (FISH), all of the intrinsic 
subtypes can be identified within cHER2+ breast cancer (12–14). 
Conversely, HER2E tumors are also identified within cHER2-neg-
ative tumors (12–14); therefore, the apparent similar classifications 
are sufficiently different that each should be considered unique.
Recently, a combined analysis of gene expression and DNA 
copy-number data has identified 10 different subtypes (known as 
IntClust 1–10) with different survival outcomes (31). Among them, 
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the IntClust-5 subtype is characterized by the amplification of the 
HER2 chromosomal amplicon (31). However, similar to cHER2+ 
heterogeneity, all of the intrinsic subtypes can be identified within 
the IntClust-5 subtype (31).
Surrogate pathology-based definitions of the intrinsic subtypes 
are an integral part of the St. Gallen Expert Consensus Guidelines 
for the recommendation of chemotherapy, endocrine therapy, and/
or anti-HER2 therapy in early breast cancer (32). However, St. 
Gallen´s criteria that divide HER2+ disease into two groups (i.e. 
HER2+/ER+ and HER2+/ER-) are driven by treatment consid-
erations mostly based on the necessity to recommend endocrine 
therapy for patients with hormone receptor-positive tumors, while 
chemotherapy and anti-HER2 therapy is recommended for both 
(32). The purpose of this work is to review the molecular features 
and the behaviors of the different subgroups of HER2+ breast 
cancer.
Methods
Patients, Samples, and Clinical Data
Two independent publicly available breast cancer datasets (The 
Cancer Genome Atlas Project [TCGA] and Molecular Taxonomy 
of Breast Cancer International Consortium [METABRIC]) were 
evaluated (12,31). TCGA includes multiple molecular data-types 
in 825 primary breast tumors: mRNA expression (17 814 unique 
genes), DNA copy-number changes (19 780 genes), protein expres-
sion (171 proteins and phosphoproteins), DNA methylation sta-
tus (21 986 CpG sites of 14 475 genes), miRNA expression (306 
transcripts) and whole exome somatic mutations. All data is pub-
licly available at TCGA website (http://cancergenome.nih.gov/) 
(12). The METABRIC dataset (31) includes breast cancer-specific 
survival data as well as whole gene expression and DNA copy-
number data of 1992 resected primary breast tumors. No patient 
with cHER2+ disease received anti-HER2 therapy. All clinical 
and genomic data is publicly available at the European Genome-
phenome Archive (EGAS00000000083) (31).
HER2 Clinical Status
cHER2 status in the TCGA dataset (12) was determined using the 
2007 American Society of Clinical Oncology (ASCO)/College of 
American Pathologists (CAP) guidelines (33), and for those cases 
that lacked IHC/FISH data, DNA copy-number data was used to 
determine HER2 amplification status. In the METABRIC data set, 
cHER2 status was based on DNA copy-number changes (31). Of 
note, classifying cHER2 based only on gene amplification may miss 
0.5%–7.3% of tumors that are overexpressing the HER2 protein 
but are HER2 non-amplified (33). Tumor samples without cHER2 
status were excluded from the analysis.
PAM50 Subtyping
Intrinsic subtyping was performed using the research-based 
50-gene prediction analysis of microarray (PAM50) subtype pre-
dictor, which classifies tumors into the following groups: Luminal 
A, Luminal B, HER2E, Basal-like and Normal-like (13). Samples 
without PAM50 data, or those identified as Normal-like (which 
often represent inadequate tumor cellularity), were excluded from 
the analysis. From TCGA, we used the subtype calls as previously 
reported (12). From the METABRIC dataset, we applied the 
PAM50 predictor in the normalized gene expression data obtained 
from the EGA website after performing median centering of the 
PAM50 genes and column standardization.
Statistical Analysis
Statistically significant differences in molecular features between 
groups were evaluated using an unpaired two class Significance 
Analysis of Microarrays (SAM) (34). Differences in the distribution 
of subtypes in cHER2+ vs cHER2-negative disease were analyzed 
by the chi-square (χ2) test or the Fisher´s exact test. Estimates of 
breast cancer-specific survival were from the Kaplan-Meier curves 
and tests of differences by the log-rank test. Univariate and multi-
variable Cox-models were used to test the independent prognostic 
significance of each variable. The assumption of proportionality 
was verified by estimating the slope of the Schoenfeld residuals.
To test the prognostic contribution of cHER2 status and the 
PAM50 subtypes, we estimated the log likelihood ratio statistic of 
each variable as an addition to a model containing the following 
clinical variables in the METABRIC dataset: cohort (discovery 
vs validation), tumor size, nodal status, systemic treatment (none, 
endocrine therapy only, endocrine and cytotoxic therapies) and 
menopausal status (31). In addition, we estimated the log likelihood 
ratio statistic of each variable as an addition to a model containing 
clinical variables, and the other variable being evaluated (cHER2 
status or PAM50 subtypes). Finally, we repeated the same analysis 
using the METABRIC 10-subtype classification (IntClust) and the 
PAM50 subtypes in the validation cohort only (13,31). The perfor-
mance of each variable was also compared using receiver operating 
characteristic (ROC) curve analysis. All statistical tests were two 
sided, and the statistical significance level was set to less than 0.05.
results
Distribution of the Intrinsic Subtypes Based on 
cHER2 Status
Clinical-pathological features, subtype distribution, and key 
molecular data-types for 481 clinically HER2+ (cHER2+) tumors 
were evaluated from two independent datasets of primary breast 
cancer (Table 1). In a combined analysis of both datasets, all intrin-
sic subtypes were identified regardless of cHER2 status (Figure 1), 
although HER2E tumors were far more frequent among cHER2+ 
disease (47.0% vs 7.1%). Overall, cHER2-positivity enriched 
6.62-fold for the HER2E subtype (P < .001, χ2 test) and dimin-
ished 3.65-fold and 1.66-fold for the Luminal A (10.7% vs 39.0%) 
and Basal-like (14.1% vs 23.4%) subtypes, respectively (P < .001 
for both, χ2 test). The proportion of Luminal B tumors based on 
cHER2 status (28.2% in cHER2+ and 30.4% in cHER2-negative) 
was not statistically significantly different (P = .39, χ2 test). Counter 
to common perception, while there were more Luminal B (28.2%) 
than Luminal A (10.7%) tumors, both luminal subtypes were rep-
resented within cHER2+ disease (32).
Gene Expression Features of the Intrinsic Subtypes 
Based on cHER2 Status
Similar distributions of cHER2-positivity were identified in each 
subtype across both datasets (Table  2), except for the Basal-like 
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subtype (2.1% of cHER2+ in TCGA vs 17.4% of cHER2+ in 
METABRIC, P < .001, Fisher´s exact test). In both datasets com-
bined, the incidence of cHER2-positivity was 64.6%, 20.0%, 
14.4%, and 7.3% in HER2E, Luminal B, Basal-like, and Luminal 
A subtypes, respectively.
Next, we determined in each subtype of the METABRIC data-
set how many genes were differentially expressed between cHER2+ 
and cHER2-negative tumors (31). Interestingly, only 0.3%, 1.2%, 
1.2%, and 3.9% of all genes evaluated (n = 25,186) were found dif-
ferentially expressed (False Discovery Rate of 0%) within Luminal 
A, Luminal B, Basal-like, and HER2E subtypes, respectively 
(Table 2). In each subtype, the top 100 genes statistically signifi-
cantly up-regulated in cHER2+ tumors were found enriched for 
genes located in the 17q12 and 17q21 DNA amplicons, such as 
HER2, GRB7, ORMLD3, PNMT, and STARD3. Interestingly, 
among cHER2+ tumors, HER2 gene expression (and the expres-
sion of other 17q12 amplicon genes) was statistically significantly 
higher in cHER2+/HER2E, or cHER2+/Basal-like tumors than in 
cHER2+/Luminal A or cHER2+/Luminal B tumors (Figure 2A).
A similar analysis in the TCGA dataset, which has a lower num-
ber of samples compared to METABRIC, revealed a lower num-
ber of differentially expressed genes (13 to 44) between cHER2+ 
and cHER2-negative tumors within each subtype (12). However, 
most of the up-regulated genes (72.7%–95.2%) in cHER2+ tumors 
of each subtype were also found located in the 17q12 and 17q21 
amplicon regions.
To further explore the degree of impact of HER2 amplifica-
tion on global gene expression in each subtype, we performed a 
clustering analysis in the METABRIC dataset of the most vari-
able genes (n = 13 497) across the four subtypes based on cHER2 
status (Figure 2B; Supplementary Figure 1, available online) (31). 
The result revealed that despite the higher expression of 17q genes 
in cHER2+ tumors compared to cHER2-negative tumors, the 
overall profile of the subtypes is largely maintained regardless of 
cHER2 status, except for the HER2E subtype, in which we found 
HER2E/cHER2+ tumors to be more similar to Basal-like tumors 
than HER2E/cHER2-negative tumors, although these HER2E/
cHER2+ tumors were still far away from being Basal-like. Similar 
clustering results were obtained with the ~1900 intrinsic gene list 
(13) (data not shown).
Additional Molecular Features of the Intrinsic Subtype 
Based on HER2 Status
The TCGA dataset offers the opportunity to interrogate molecu-
lar data-types such as protein expression, miRNA expression, and 
DNA methylation status (Supplementary Table 1, available online)
(12). Similar to gene expression, minor molecular differences 
between cHER2+ and cHER2-negative tumors within each sub-
type were identified. Indeed, only 6 to 12 proteins or phospho-
proteins (representing 3.5% to 7.0% of all proteins evaluated) were 
found differentially expressed in each subtype according to cHER2 
status, and the vast majority of proteins up-regulated in cHER2+ 
tumors, such as HER2, RPS6KB1 and ACACA, originate from 
genes located in the 17q DNA region. Regarding DNA methyla-
tion and miRNA expression, less than 0.3% CpG islands or miR-
NAs were found statistically significantly methylated or expressed 
in cHER2+ tumors compared to cHER2-negative tumors within 
each subtype.
Survival Outcomes of the Intrinsic Subtypes Based on 
cHER2 Status
To evaluate the impact of HER2 amplification on survival either 
alone or in the context of the subtypes, we used the METABRIC 
dataset of 1711 patients with resected primary tumors and long-
term clinical follow up (31). Of note, all this dataset is from patients 
with newly diagnosed breast cancer and no patient-received adju-
vant trastuzumab (31). When evaluated alone, cHER2+ status was 
found statistically significantly associated with poorer breast can-
cer-specific survival (BCSS) compared to cHER2-negative status 
(hazard ratio [HR] = 1.53; 95% confidence interval [CI] = 1.26 to 
Table 1. Clinical-pathological features of the 2 breast cancer data-
sets evaluated in this study
Clinical-pathological 
features TCGA* METABRIC*
Patients, No. (%) 495 (100) 1730 (100)
Mean age (range), y 58.0 (26.0–90.0) 61.7 (22.0–96.3)
Tumor size, No. (%)
 T0-T1 123 (24.8) 732 (42.7)
 T2-T3-T4-TX 372 (75.2) 982 (57.3)
Nodal status, No. (%)
 N0 246 (49.7) 875 (51.1)
 N1-N3-NX 249 (50.3) 839 (48.9)
cHER2 status, No. (%)
 cHER2-negative 420 (84.8) 1324 (76.5)
 cHER2-positive 75 (15.2) 406 (23.5)
PAM50 subtype, No. (%)
 Luminal A 223 (45.1) 512 (29.6)
 Luminal B 122 (24.6) 539 (31.2)
 HER2-enriched 55 (11.1) 295 (17.1)
 Basal-like 95 (19.2) 384 (22.2)
Available genomic data-types
 Gene Expression Yes Yes
 DNA Copy-number Yes Yes
 Protein Expression Yes No
 DNA Methylation Yes No
 miRNA Expression Yes No
Breast cancer survival 
data
No Yes
* Inclusion criteria: primary tumors with cHER2 and PAM50 data. Normal-
like tumor samples were excluded. T = tumor stage; N = nodal stage; 
cHER2 = clinical HER2 status; TCGA = the cancer genome atlas; 
METABRIC = molecular taxonomy of breast cancer international consortium; 

















Figure 1. Distribution of the intrinsic molecular subtypes of breast can-
cer in clinical HER2 status (cHER2)-negative and cHER2+ disease in the 
combined the cancer genome atlas and molecular taxonomy of breast 
cancer international consortium dataset. cHER2 = clinical HER2 status.
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1.86; P < .001) (Figure 3A). In addition, cHER2 status provided 
independent prognostic information beyond that provided by 
clinical-pathological variables (Supplementary Figure 2, available 
online). However, the prognostic value of cHER2 status disap-
peared when subtype was taken into consideration, whereas sub-























































































































Figure  2. Gene expression patterns of the intrinsic molecular sub-
types of breast cancer based on clinical HER2 status (cHER2) status 
in the molecular taxonomy of breast cancer international consortium 
(METABRIC) dataset. A) Relative transcript abundance of estrogen 
receptor gene (ESR1) and HER2 gene (ERBB2) across the intrinsic sub-
types and based on HER2 status. The boxes represent the interquartile 
range (25th and 75th percentiles), and the horizontal line in the box rep-
resents the median value. The whiskers show the range of largest and 
smallest values. B) Hierarchical clustering of the cHER2+ and cHER2-
negative intrinsic subtypes (total of 8 classes) with 13 497 most variable 
genes in the METABRIC dataset. Sample and gene expression data from 
tumor samples of the same subtype, and of the same cHER2 status, 
have been combined into a single category. For each gene in a class, 
we calculated the standardized mean difference between the gene´s 
expression in that class, vs its overall mean expression in the dataset 
using an 8-class Significance Analyses of Microarrays on the METABRIC 
dataset. On the right panel, a heatmap of genes located in a selected 
gene cluster is shown. For both heatmaps, red color represents relative 
high gene expression, green represents relative low gene expression, 
and black represents median gene expression.
Table 2. Differentially expressed genes between clinical HER2 status (cHER2)-positive vs cHER2-negative disease within each intrinsic 
subtype of breast cancer
Subtype HER2 status*
METABRIC (n = 1730) TCGA (n = 495)
N %
No. genes 
up-regulated %† N %
No. genes 
up-regulated %‡
Luminal A cHER2+ 40 7.8 72 0.3% 14 6.3% 21 0.1
cHER2-neg 472 92.2 3 0% 209 93.7% 0 0
Luminal B cHER2+ 112 20.8 245 1.0% 20 16.4% 44 0.2
cHER2-neg 427 79.2 51 0.2% 102 83.6% 0 0
HER2-enriched cHER2+ 187 63.4 505 2.0% 39 70.9% 13 0.1
cHER2-neg 108 36.6 467 1.9% 16 29.1% 0 0
Basal-like cHER2+ 67 17.4 279 1.1% 2 2.1% NA NA
cHER2-neg 317 82.6 30 0.1% 93 97.9% NA NA
* cHER2 status was determined by single nucleotide polymorphism (SNP) arrays in the molecular taxonomy of breast cancer international consortium (METABRIC) 
dataset and immunohistochemistry (IHC) and/or fluorescence in situ hybridization (FISH) in the cancer genome atlas (TCGA) (except for samples with missing 
IHC/FISH data where SNP data was used). cHER2 = clinical HER2 status; TCGA = The Cancer Genome Atlas Project; METABRIC = molecular taxonomy of breast 
cancer international consortium.
† Proportion of genes statistically significantly up-regulated of the 25 186 unique genes evaluated in the Illumina microarray dataset.
‡ Proportion of genes statistically significantly up-regulated of the 17 814 unique genes evaluated in the 244K Agilent microarray dataset.
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cHER2 status. There was no statistically significant impact of 
HER2 amplification on BCSS within any subtype (Supplementary 
Figure 3, available online). For example, patients with Luminal A/
cHER2+ tumors showed similar survival outcomes as patients with 
Luminal A/cHER2-negative tumors (HR = 1.34; 95% CI = 0.62 to 
2.90; P = .46), and both of these groups showed a better outcome 
compared to the other subtypes regardless of their cHER2 status 
(Figure 3B; Supplementary Table 2, available online).
Finally, we compared the prognostic value of the recently 
reported 10-subtype classification (IntClust) vs intrinsic subtypes 
(31). The results revealed that the 10-subtypes do not provide addi-
tional prognostic value when subtype is taken into consideration, 
whereas intrinsic subtype does provide independent prognostic 
information beyond the one provided by the 10-subtypes (Table 3; 
Supplementary Figure 2, available online). In multivariable analy-
sis, variables that independently contributed to poor prognosis 
included clinical-pathologic factors (tumor size and nodal status), 
intrinsic subtype, and the IntClust-2 subtype (31). Similar results 
were obtained by comparing the performance of each variable using 
ROC curve analysis (Supplementary Figure 4, available online).
Discussion
Our study provides new insights into the biological and clinical het-
erogeneity of cHER2+ breast cancers. Our results suggest that: 1) all 
the intrinsic molecular subtypes can be identified within cHER2+ 
disease; 2) cHER2+ tumors of a given subtype are largely undistin-
guishable from cHER2-negative tumors of the same subtype except 
for the high expression of genes in or near the HER2 amplicon on 
17q in cHER2+ tumors; 3) within cHER2+ tumors, HER2 is more 
highly expressed in the HER2E or Basal-like tumors than Luminal 
A or B tumors, and all cHER2+ tumors demonstrate more HER2 
mRNA expression than cHER2-negative tumors, regardless of 
intrinsic subtype; 4) HER2 amplification per se does not statistically 
significantly affect survival outcomes once intrinsic subtype is taken 
into account; and 5) clinical HER2 status, or the recently reported 
10-subtype classes, do not provide additional prognostic informa-
tion beyond that provided by the intrinsic subtypes.
At first glance, the observation that HER2 amplification does 
not translate into large changes in the expression of intracellular 
signaling pathways (as assessed by gene or reverse phase protein 
array protein expression) within a given subtype might seem coun-
terintuitive since HER2 is considered an activating oncogene of 
the MAP-Kinase and PI3K/AKT/mTOR signaling pathways lead-
ing to cell growth and increased proliferation (1, 35–37). However, 
it is important to note that our results do not preclude a potential 
role of HER2 within each subtype, but rather highlight that the 
magnitude of the impact of HER2 amplification as a single entity is 
small compared to the magnitude of genome expression as a whole, 
and that the biologically distinct intrinsic subtypes appear to retain 
their individual characteristics and behavior regardless of cHER2 
status. In any case, the levels of HER2 amplification/overexpres-
sion are higher in the HER2E than in the rest of subtypes. Overall, 
these data suggest that, although HER2 does not induce large 
molecular changes in the HER2E subtype, HER2 is still likely to 
be the main driver of the cHER2+/HER2E subtype. On the other 
hand, the molecular impact of HER2 amplification in the other 
subtypes seems to be minor.
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Figure 3. Kaplan-Meier 10-year breast cancer-specific survival analyses in the molecular taxonomy of breast cancer international consortium data-
set (all patients). A) Based on cHER2 status. B) Based on intrinsic subtype and cHER2 status. Tables of the numbers of patients at risk in each group 
at various time points are below each graph. Statistically significant differences were determined by two-sided log-rank test.
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The clinical relevance of the luminal vs non-luminal distinc-
tion within cHER2+ breast cancer is not new. Two studies have 
shown that hormone receptor status determined by IHC identifies 
two main groups of cHER2+ tumors with different survival out-
comes (38,39). In the 4-year follow-up of the N9831 and National 
Surgical Adjuvant Breast and Bowel Project B-31 adjuvant trials 
of trastuzumab in HER2+ disease (n = 4045), hormone receptor-
positive disease was found statistically significantly associated with 
approximately 40% increased disease-free survival and overall sur-
vival, compared to hormone receptor-negative disease (38). This 
association of hormone receptor status with survival was found to 
be independent of the main clinical-pathological variables, includ-
ing trastuzumab administration (38). Similar data was observed 
in a prospective cohort study of 3394 patients with stage I to III 
cHER2+ breast cancer from National Comprehensive Cancer 
Network centers (39). In both studies, hormone receptor-negative 
disease experienced more cancer relapse in the first 5 years than 
hormone receptor-positive (38,39). Interestingly, patients with 
hormone receptor-negative tumors were less likely to experience 
first recurrence in bone and more likely to recur in brain, com-
pared to patients with hormone receptor-positive tumors (39).
Hormone receptor status in cHER2+ breast cancer is also 
predictive of pathological complete response (pCR) after neoad-
juvant anti-HER2 therapy in combination with chemotherapy 
across multiple clinical trials (10,40-43). In Neoadjuvant Lapatinib 
and/or Trastuzumab Treatment Optimisation (NeoALTTO), the 
pCR rates after paclitaxel in combination with one of the three 
anti-HER2 regimens (lapatinib, trastuzumab, and lapatinib com-
bined with trastuzumab) were higher in hormone receptor-nega-
tive disease compared to hormone receptor-positive disease (42). 
Although not statistically significant, similar response data has 
been reported in the Cancer and Leukemia Group B (CALGB) 
40601 neoadjuvant trial, which has a similar design to NeoALTTO 
(42,44). Interestingly, PAM50 data in a subset of samples of the 
CALGB40601 trial (n = 160) identified all the intrinsic subtypes 
within HER2+ disease and global pCR rates as 75%, 36%, 35%, 
and 29% in the HER2E, Basal-like, Luminal A, and Luminal B 
subtypes, respectively (44). Similar results with the PAM50 predic-
tor were observed in patients with cHER2+ disease treated with 
neoadjuvant trastuzumab and anthracycline/taxane-based chemo-
therapy in the neoadjuvant trastuzumab in locally advanced breast 
cancer trial (45). Overall, these data suggest that within cHER2+ 
tumors, the HER2E subtype benefits the most from anti-HER2-
based chemotherapy.
There are limitations to this study that must be acknowledged. 
The survival data is derived from one dataset, METABRIC, which is 
a very large cohort of nearly 2000 tumors that were heterogeneously 
treated. None received HER2-targeted therapy so the prognostic 
implications detected represent historical behavior. There is no doubt 
that modern HER2-targeting changes the natural history of HER2-
positive breast cancer. Additional datasets that have RNA-based 
assays and survival will be needed to confirm the findings related to 
Table 3. Cox model disease 10-year breast cancer specific-survival analysis in the molecular taxonomy of breast cancer international 
consortium validation set (n = 818)
Variables
Univariate analysis Multivariable analysis
HR (95% CI) P* HR (95% CI) P*
Tumor size
 T2 vs T0-1 2.08 (1.51 to 2.87) <.001 1.61 (1.16 to 2.25) .005
 T3 vs T0-1 3.78 (2.19 to 6.52) <.001 1.92 (1.07 to 3.45) .03
Nodal status
 1–3 vs 0 2.22 (1.56 to 3.15) <.001 2.07 (1.34 to 3.22) .001
 >3 vs 0 5.43 (3.79 to 7.79) <.001 4.44 (2.82 to 6.99) <.001
Postmenopausal vs Premen. 0.74 (0.53 to 1.02) .07 1.01 (0.68 to 1.50) .96
PAM50 Subtype  
(Luminal A as reference)
 Luminal B 3.34 (2.04 to 5.42) <.001 2.51 (1.47 to 4.28) .001
 Basal-like 4.03 (2.47 to 6.58) <.001 3.35 (1.73 to 6.49) <.001
 HER2E 4.92 (2.99 to 8.08) <.001 3.33 (1.81 to 6.14) <.001
Systemic treatment
 Chemo vs None 3.87 (2.46 to 6.09) <.001 1.15 (0.61 to 2.17) .66
 Chemo/HT vs None 1.63 (1.09 to 2.43) .02 1.02 (0.61 to 1.70) .95
 HT vs None 3.93 (2.33 to 6.65) <.001 1.23 (0.63 to 2.38) .55
Curtis et al. Subtypes  
(IntClustMemb3 as reference)
 IntClustMemb1 3.43 (1.56 to 7.56) .002 1.56 (0.68 to 3.56) .29
 IntClustMemb2 5.26 (2.19 to 12.64) <.001 3.24 (1.28 to 8.16) .01
 IntClustMemb4 2.55 (1.19 to 5.44) .02 1.40 (0.63 to 3.13) .42
 IntClustMemb5 5.65 (2.81 to 11.37) <.001 2.03 (0.93 to 4.45) .08
 IntClustMemb6 4.09 (1.77 to 9.46) <.001 2.31 (0.98 to 5.47) .06
 IntClustMemb7 1.33 (0.54 to 3.27) .54 1.33 (0.54 to 3.28) .54
 IntClustMemb8 1.75 (0.84 to 3.67) .14 1.39 (0.66 to 2.96) .39
 IntClustMemb9 3.53 (1.67 to 7.46) .001 1.58 (0.72 to 3.51) .26
 IntClustMemb10 3.70 (1.84 to 7.46) <.001 1.32 (0.57 to 3.06) .52
* Calculated using Cox proportional hazards two-sided test. HR = hazard ratio; CI = confidence interval; HT = hormone therapy; Chemo = chemotherapy; T = tumor 
stage; METABRIC = molecular taxonomy of breast cancer international consortium; PAM50 = 50-gene prediction analysis of microarray.
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outcome and will extend this to the impact of HER2 targeting by 
subtype. Furthermore, the identification of genes that are up- and 
down-regulated among cHER2-positive breast cancer of various sub-
types is intriguing but must be considered exploratory. Fortunately, 
there are over 1000 patients treated on large cooperative group neo-
adjuvant studies with RNA-based assays planned that can be used to 
further and confirm our findings. Although central confirmation of 
clinical assay status could not be performed in these large merged 
datasets, it is reassuring that the primary findings by mRNA regard-
ing expression of HER2-related genes, regardless of intrinsic subtype, 
corresponded with the clinical HER2 status. Finally, it is important 
to point out that classification of HER2 status based on gene ampli-
fication only might miss 5%–8% of tumors that are overexpressing 
HER2 and that might benefit from anti-HER2 therapies.
To conclude, cHER2+ disease appears as heterogeneous as the 
other clinical subsets of breast cancer. When the intrinsic subtypes 
are taken into account, HER2 amplification does not translate into 
large changes in the expression of downstream signaling pathways 
or differences in patient survival outcomes. Thus, the mechanisms 
of action and the effectiveness of anti-HER2 therapies on cHER2+ 
tumors might depend in part upon their intrinsic tumor profile, 
with the cHER2+/HER2E subtype tumors showing the likely 
greatest impact for outcomes and HER2-targeting. Finally, sub-
typing might help identify patients with cHER2+ disease that need 
less intensive systemic therapy.
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